![Richard Auburn](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Richard Auburn
Director/Board Member at Singula Bio Ltd.
Richard Auburn active positions
Companies | Position | Start | End |
---|---|---|---|
Oxford University Innovation Ltd.
![]() Oxford University Innovation Ltd. Investment ManagersFinance Oxford University Innovation Ltd (Oxford University Innovation) is a venture capital subsidiary of University of Oxford founded in 1987 and spun out in 2010. The firm is headquartered in London, United Kingdom. | Private Equity Investor | 01/01/2015 | - |
Singula Bio Ltd.
![]() Singula Bio Ltd. BiotechnologyHealth Technology Singula Bio Ltd. is a seed-stage biotechnology company based in Oxford, UK. The British company was spun out of the University of Oxford and is focused on developing novel neoantigen-based cell therapies for patients with solid tumors. The company was founded by Vincenzo Cerundolo, Enda McVeigh, Ahmed Ahmed. | Director/Board Member | 01/11/2020 | - |
Career history of Richard Auburn
Training of Richard Auburn
University of Cambridge | Graduate Degree |
University of Aberdeen | Undergraduate Degree |
Statistics
International
United Kingdom | 5 |
Operational
Private Equity Investor | 1 |
Director/Board Member | 1 |
Graduate Degree | 1 |
Sectoral
Consumer Services | 3 |
Finance | 2 |
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Oxford University Innovation Ltd.
![]() Oxford University Innovation Ltd. Investment ManagersFinance Oxford University Innovation Ltd (Oxford University Innovation) is a venture capital subsidiary of University of Oxford founded in 1987 and spun out in 2010. The firm is headquartered in London, United Kingdom. | Finance |
Singula Bio Ltd.
![]() Singula Bio Ltd. BiotechnologyHealth Technology Singula Bio Ltd. is a seed-stage biotechnology company based in Oxford, UK. The British company was spun out of the University of Oxford and is focused on developing novel neoantigen-based cell therapies for patients with solid tumors. The company was founded by Vincenzo Cerundolo, Enda McVeigh, Ahmed Ahmed. | Health Technology |
- Stock Market
- Insiders
- Richard Auburn
- Experience